You are here
The FDA Approves Lithium Carbonate Extended-Release Tablets, Generic Version of Lithobid
Although Able is the second company to receive an ANDA approval for this product, Able anticipates it will be the first company to ship the generic equivalent of Lithobid® Slow-Release Tablets.
Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Since March 2001, Able has received 28 ANDA approvals. Further information on Able may be found on the Company's web site, www.ablelabs.com.